The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback